Dali Pharmaceutical Co Ltd
603963
Company Profile
Business description
Dali Pharmaceutical Co Ltd operates in the pharmaceutical manufacturing industry. It is engaged in the research and development and production of Chinese and Western medicine injection products. The company's main products are Zhongjing Brand Xingnaojing Injection, Shenmai Injection, Astragalus Injection, Brighten A Injection and Cell Diphosphocholine injection.
Contact
No. 118, Huancheng West Road
Yunnan Province
Xiaguan Town
Dali671000
CHNT: +86 8728880055
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
272
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,754.70 | 49.70 | 0.57% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,745.33 | 36.67 | -0.08% |
| FTSE 100 | 8,359.41 | 46.52 | 0.56% |
| HKSE | 19,746.32 | 196.03 | 1.00% |
| NASDAQ | 19,457.98 | 54.03 | 0.28% |
| Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
| NZX 50 Index | 13,093.18 | 21.50 | -0.16% |
| S&P 500 | 6,050.76 | 3.61 | 0.06% |
| S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
| SSE Composite Index | 3,378.81 | 14.82 | 0.44% |